- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01216982
Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders
Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders: A Mood Resilience Trial
Stress-related disorders are among the most prevalent and expensive medical consequences of participation in military operations. Omega-3 fatty acids EPA/DHA derived from fish oil are known to benefit both neuronal development in the young, and cognition and mood in various populations.
It is possible that soldiers receiving Omega-3 EPA/DHA will exhibit significantly higher cognitive performance, better affect/mood state, and less combat stress symptomatology compared to the placebo after 12 weeks of supplementation. A goal would be to reduce the prevalence of combat stress injuries in military personnel.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Camp Taji, Iraq, 09378
- US Military Base
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- US Army deployed personnel
- score on a mood questionnaire
Exclusion Criteria:
- currently consume omega-3 fish oil supplements
- are currently taking antidepressant or other medications for psychiatric purposes
- pregnant
- known fish or shellfish allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Lovaza, omega-3 fatty acid ethyl ester
|
Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
Other Names:
|
Placebo Comparator: Placebo
one gram corn oil in a soft gelatin capsule
|
Three 1g corn oil capsules/day for three months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
primary psychometric assessment battery
Time Frame: 3 months
|
Specific components include: Zung Depression Scale (ZDS) Zung Anxiety Scale (ZAS) Pittsburgh Sleep Quality Index (PSQI) Epworth Sleepiness Scale (ESS) |
3 months
|
omega-3 fatty acid status
Time Frame: 3 months
|
finger-prick blood spot is collected for determination of fatty acid composition and profile.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
secondary psychometric assessment battery
Time Frame: 3 months
|
This battery will generate index scores in the area of: Memory, Psychomotor Speed, Reaction Time, Cognitive Flexibility, and Complex Attention. It will also include the Alcohol Use Identification Test (AUdIT). Military-specific components include Post-Deployment Health Assessment (PDHA), Neurobehavioral Symptom Inventory (NSI), Combat Exposure Scale (CES), and parts of the Deployment Risk and Resilience Inventory (edited). |
3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel T Johnston, MD, MPH, United States Department of Defense
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M-10023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Lovaza, omega-3 fatty acid ethyl ester
-
Brigham and Women's HospitalNational Institute of General Medical Sciences (NIGMS)CompletedBlister | Inflammation; Skin | ResolutionUnited States
-
University of Kansas Medical CenterActive, not recruitingColorectal Cancer | Lynch SyndromeUnited States
-
Boston Children's HospitalGlaxoSmithKline; Harvard UniversityWithdrawnLiver Disease | Short Bowel SyndromeUnited States
-
University of UtahGlaxoSmithKlineWithdrawnEffects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in HypertriglyceridemiaHypertriglyceridemiaUnited States
-
University of IowaGlaxoSmithKlineTerminated
-
University of MichiganGlaxoSmithKlineTerminated
-
Massachusetts General HospitalHarvard School of Public Health (HSPH)WithdrawnColon CancerUnited States
-
University of Illinois at ChicagoTerminatedNonalcoholic Steatohepatitis (NASH) | Hepatic SteatosisUnited States
-
Columbia UniversityGlaxoSmithKlineTerminated